2,6-Dichloroquinoxaline | CAS:18671-97-1

We serve 2,6-Dichloroquinoxaline CAS:18671-97-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
2,6-Dichloroquinoxaline

CAS No: 18671-97-1
Product Name: 2,6-Dichloroquinoxaline
Other Name:
2,6-Dichloroquinoxaline
 
Density: 1.5±0.1 g/cm3
Boiling Point: 278.7±35.0 °C at 760 mmHg
Melting Point: 153-157 °C(lit.)
Molecular Formula: C8H4Cl2N2
Molecular Weight: 199.037
Flash Point: 149.1±11.5 °C
Exact Mass: 197.975159
PSA: 25.78000
LogP: 2.95
Vapour Pressure: 0.0±0.6 mmHg at 25°C
Index of Refraction: 1.671
 
Specification
Appearance: White solid
Assay: ≥99.0%
Loss on drying: ≤0.5%
 
Application
Intermediates of Quizalofop-Ethyl CAS: 76578-14-8.
Be used as pesticide intermediate, mainly used to synthesize herbicide Quizalofop-Ethyl.
 
Package: 25kg/drum, can also be designed according to customer requirements.
Storage: Store in cool place. Keep container tightly closed in a dry and well-ventilated place.



Contact us for information like 2,6-Dichloroquinoxaline chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2,6-Dichloroquinoxaline physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2,6-Dichloroquinoxaline Use and application,2,6-Dichloroquinoxaline technical grade,usp/ep/jp grade.


Related News: Others — somewhat more cynically — wondered if this was a concerted effort to promote certain herbal products to boost their makers’ share prices ahead of the Chinese stock market’s re-opening Monday.cyclobutane-1,1-dicarboxylic acid manufacturer Active Pharmaceutical Ingredients (APIs): Pharmaceutical active ingredients, which are the basic substances that constitute the pharmacological effects of pharmaceuticals, and are prepared by chemical synthesis, plant extraction, or biotechnology.2,3-Diethyl-5-methylpyrazine supplier It is estimated that the size of China’s CMO market has reached about USD 5 billion. With the implementation and further implementation of the MAH system (the core is to separate drug marketing authorization from drug production authorization) in China, it is expected to promote the outbreak of the domestic drug CMO industry. It will grow at a rate of 20% to 30%, of which patented APIs occupy a larger proportion.4-phenoxyphenol vendor Due to the cyclic nature of the upstream chemical products of the API, it is expected that the impact of price fluctuations of raw materials on the performance of API companies is unavoidable, but companies with thick product lines and the ability to produce intermediates are expected to minimize the upstream price impact.For example, an active ingredient to relieve pain is included in a painkiller.